CASE REPORT article
Front. Med.
Sec. Pulmonary Medicine
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1579601
A Case Report: Anaphylactic Shock Induced by Cefoperazone Sodium and Sulbactam Sodium for Injection
Provisionally accepted
- Hebei General Hospital, Shijiazhuang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Rationale: Cefoperazone-sulbactam is a widely used antibiotic in clinical practice, and anaphylactic shock is a severe adverse drug reaction. Previous literature has rarely reported cases of anaphylactic shock induced by cefoperazone-sulbactam. Patient Concerns: A 38-year-old male patient who underwent surgery for cerebral hemorrhage developed fever, with considerations of pulmonary and urinary tract infections. Following the administration of injectable cefoperazone-sulbactam, he experienced anaphylactic shock. Diagnosis: Anaphylactic shock was suspected to be caused by injectable cefoperazone-sulbactam.The patient was administered a subcutaneous injection of 1 mg epinephrine, followed by continuous infusion of 10 mg norepinephrine in 45 mL of 5% glucose solution via a pump. Additionally, assisted ventilation with a respirator and fluid resuscitation were provided. Outcome: The patient was discharged with improved symptoms. Lessons: To prevent serious adverse reactions, it is essential to strictly adhere to indications and contraindications to avoid misuse and minimize the occurrence of adverse effects. Prior to medication administration, a thorough inquiry into the patient's drug allergy history and family history should be conducted.
Keywords: case report, Injectable cefoperazone-sulbactam, Anaphylactic shock, adverse drug reactions, antibiotics
Received: 19 Feb 2025; Accepted: 05 Jun 2025.
Copyright: © 2025 Liu, Mm, Xie, Bm and Yin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Yu Yin, Hebei General Hospital, Shijiazhuang, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.